Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement). Ligand terminated Viking’s TR-Beta Program, including VK2809 and VK0214, effective May 4, 2026.
LIGAND PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- Ligand terminated Viking’s TR-Beta Program, including VK2809 and VK0214, effective May 4, 2026
- Termination follows Ligand’s allegation that Viking breached its commercially reasonable development obligations
- Viking disputes Ligand’s termination right, creating contractual and potential litigation uncertainty
- Viking must provide Ligand a worldwide, sublicensable license to relevant technology at low-single-digit royalties if termination stands
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIGAND PHARMACEUTICALS INC 8-K filings
Get the next LGND 8-K as it lands
Follow LGND for push alerts, or ask the research agent what this filing means.